The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Intolerance to Statins: Mechanisms and Management
Open accessAbstract
S tatins are considered very effectivein reducing cardiovascular morbid-ity and mortality in high-risk pa-tients. However, although adherence to statins improves morbidity and mortality (1), it remains suboptimal (2). One of the most important causes of nonadherence is the so-called statin intolerance, mainly because of muscle-related symptoms. These symptoms most often consist of myalgia unaccompanied by significant creatine kinase (CK) elevations. Less of-ten, myositis (elevated CK.10 times the upper limit of normal) or rhabdomyolysis (CK level.10,000 IU/L or accompanied by significant elevation in creatinine level) develops. In randomized controlled trials, the incidence of statin myopathy is ~1.5– 5.0 % (3). However, this low incidence may be misleading for several reasons. First, in most studies patients with a his-tory of statin intolerance were excluded. Other studies had a single-blinded statin run-in phase, and patients experiencing muscle-related symptoms or CK eleva-tions during this phase were excluded. Patients who tend to be at risk for devel-oping muscle-related symptoms, such as women, elderly patients, and patients with significant comorbidity, who com-prise a large proportion of statin-treated patients in real-life settings, are underrep-resented in randomized controlled trials. Some studies have definedmuscle-related effects by elevated CK levels only, disre-garding myalgia. Last but not least, pa-tients enrolled in studies might be motivated and so minimize reporting of mild myalgias, thus leading to underesti-mation of the magnitude of the problem. Data concerning real-life incidence of statin-related myopathy are scarce. In the
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226
Plant sterol and stanol margarines and health
Law, M. (2000) · BMJ · doi:10.1136/bmj.320.7238.861 · Cited by 729 · cited 1×
“Adding phytosterols to a hearthealthy diet may produce ~10% decrease in LDL cholesterol (36).”
BackgroundStatin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
Outcomes in 45 Patients With Statin-Associated Myopathy
Hansen, K. E., Hildebrand, J. P., Ferguson, E. E., & Stein, J. H. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.22.2671 · Cited by 280
Statin Safety: An Overview and Assessment of the Data—2005
Bays, H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.006 · Cited by 264
Bouitbir, J., Charles, A.-L., Echaniz-Laguna, A., Kindo, M., Daussin, F., Auwerx, J., Piquard, F., Geny, B., & Zoll, J. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr224 · Cited by 256 · cited 1×
“In human atrial cells, statins triggered transcriptional activation of mitochondrial biogenesis, probably by enhancing antioxidant capacity, whereas in skeletal muscle statins induced high oxidative stress responsible for transcriptional deactivation of mitochondrial biogenesis as well as mitochondrial dysfunction (20…”
BackgroundGenetic risk factors associated with lipid-lowering drug-induced myopathies
Vladutiu, G. D., Simmons, Z., Isackson, P. J., Tarnopolsky, M., Peltier, W. L., Barboi, A. C., Sripathi, N., Wortmann, R. L., & Phillips, P. S. (2006) · Muscle & Nerve · doi:10.1002/mus.20567 · Cited by 253
Human skeletal muscle drug transporters determine local exposure and toxicity of statins
Knauer, M. J., Urquhart, B. L., Meyer zu Schwabedissen, H. E., Schwarz, U. I., Lemke, C. J., Leake, B. F., Kim, R. B., & Tirona, R. G. (2010) · Circulation Research · doi:10.1161/circresaha.109.203596 · Cited by 222
Effect of coenzyme Q10 supplementation on simvastatin-induced myalgia
Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., George, P. M., & Scott, R. S. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.030 · Cited by 185
Muscle coenzyme Q10 level in statin-related myopathy
Lamperti, C., Naini, A. B., Lucchini, V., Prelle, A., Bresolin, N., Moggio, M., Sciacco, M., Kaufmann, P., & DiMauro, S. (2005) · Archives of Neurology · doi:10.1001/archneur.62.11.1709 · Cited by 178 · cited 2×
“However, another study demonstrated that muscle structure was essentially normal in 14 of 18 patients with statin-induced increased CK levels (17).”
BackgroundResultLaaksonen, R., Jokelainen, K., Laakso, J., Sahi, T., Härkönen, M., Tikkanen, M. J., & Himberg, J.-J. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89180-1 · Cited by 171 · cited 1×
“Other studies, testing mitochondrial function by the activity of complex III of the mitochondrial respiratory chain (17) or by directly measuring concentrations of high-energy phosphates (19), found no changes in statin-treated patients, suggesting that mitochondrial function was not compromised.”
BackgroundChodick, G., Shalev, V., Gerber, Y., Heymann, A. D., Silber, H., Simah, V., & Kokia, E. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.012 · Cited by 145
Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin
Schick, B. A., Laaksonen, R., Frohlich, J. J., Päivä, H., Lehtimäki, T., Humphries, K. H., & Côté, H. C. F. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100124 · Cited by 103
Stein, E. A., Ballantyne, C. M., Windler, E., Sirnes, P. A., Sussekov, A., Yigit, Z., Seper, C., & Gimpelewicz, C. R. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.099 · Cited by 102
Statin use and musculoskeletal pain among adults with and without arthritis
Buettner, C., Rippberger, M. J., Smith, J. K., Leveille, S. G., Davis, R. B., & Mittleman, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.08.007 · Cited by 102
Cited by
Statin Toxicity: Mechanistic Insights and Clinical Implications
Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 757
Thyroid dysfunction and diabetes mellitus: two closely associated disorders
Biondi, B., Kahaly, G. J., & Robertson, R. P. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00163 · Cited by 598
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.49807 · Cited by 378
Statin Therapy: Review of Safety and Potential Side Effects.
Ramkumar, S., Raghunath, A., & Raghunath, S. (2016) · PubMed · doi:10.6515/acs20160611a · Cited by 358
Serban, M.-C., Colantonio, L. D., Manthripragada, A. D., Monda, K. L., Bittner, V. A., Banach, M., Chen, L., Huang, L., Dent, R., Kent, S. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.036 · Cited by 318
Metadata
- Authors
- Bitzur, R., Cohen, H., Kamari, Y., & Harats, D.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-17
- Volume
- 36
- Issue
- Supplement_2
- Pages
- S325-S330
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2107969192
- Cited by
- 179
- References
- 19
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.